Genenta Science is an Italian clinical-stage biotech company focused on developing gene therapies using hematopoietic stem cells for treating solid tumors. Its lead candidate, Temferon, is currently undergoing Phase 1/2a clinical trials for glioblastoma multiforme in patients with this gene. Genenta Science aims to develop Temferon for other uses as well, including locally advanced hepatocellular carcinoma and intra-hepatic cholangiocarcinoma.